Literature DB >> 3085981

Determination of indoxyl sulfate in plasma of patients with renal failure by use of ion-pairing liquid chromatography.

L A Stanfel, P F Gulyassy, E A Jarrard.   

Abstract

Using our newly developed ion-pairing reversed-phase liquid-chromatographic method for assay of indoxyl sulfate, we measured its concentration in plasma of normal subjects and patients in various degrees of renal failure. Response was linear over the range of 50 to 25 000 pmol of indoxyl sulfate injected into the chromatograph. We demonstrated the specificity of the assay for azotemic plasma by using enzymatic conversion with a sulfatase. For a moderately above-normal indoxyl sulfate concentration in azotemic plasma of 134 mumol/L (29 mg/L), the within-day CV was 1.6%, the day-to-day CV 2.8%. Mean analytical recovery was 101.0% (CV = 2.8%). Over a range of 29 to 192 mg of creatinine per liter of plasma (x), indoxyl sulfate (y) concentration (in mumol/L) was positively correlated (y = 1.30x + 0.43). This method should prove valuable for further study of uremic toxins.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3085981

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  8 in total

1.  Hepatic microsomal metabolism of indole to indoxyl, a precursor of indoxyl sulfate.

Authors:  E Banoglu; G G Jha; R S King
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

2.  Klotho Protects Against Indoxyl Sulphate-Induced Myocardial Hypertrophy.

Authors:  Ke Yang; Cheng Wang; Ling Nie; Xiaohui Zhao; Jun Gu; Xu Guan; Song Wang; Tangli Xiao; Xinli Xu; Ting He; Xuefeng Xia; Junping Wang; Jinghong Zhao
Journal:  J Am Soc Nephrol       Date:  2015-03-24       Impact factor: 10.121

3.  p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients.

Authors:  Björn K I Meijers; Henriette De Loor; Bert Bammens; Kristin Verbeke; Yves Vanrenterghem; Pieter Evenepoel
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 8.237

4.  Inhibitory effect of free fatty acids on plasma protein binding of disopyramide in haemodialysis patients.

Authors:  T Horiuchi; I Johno; T Hasegawa; S Kitazawa; M Goto; T Hata
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Purple Urine Bag Syndrome- An Alarming Situation.

Authors:  M S Faridi; Md Jawaid Rahman; Naloh Mibang; N Shantajit; Khumukchum Somarendra
Journal:  J Clin Diagn Res       Date:  2016-02-01

6.  Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate.

Authors:  Suree Lekawanvijit; Andrew R Kompa; Minako Manabe; Bing H Wang; Robyn G Langham; Fuyuhiko Nishijima; Darren J Kelly; Henry Krum
Journal:  PLoS One       Date:  2012-07-19       Impact factor: 3.240

7.  Purple urine bag syndrome: time for awareness.

Authors:  Reginald Alex; Krishna Manjunath; Rajan Srinivasan; Gopal Basu
Journal:  J Family Med Prim Care       Date:  2015 Jan-Mar

8.  Ligand binding to the FA3-FA4 cleft inhibits the esterase-like activity of human serum albumin.

Authors:  Paolo Ascenzi; Loris Leboffe; Alessandra di Masi; Viviana Trezza; Gabriella Fanali; Magda Gioia; Massimo Coletta; Mauro Fasano
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.